BEIJING – After the first injection, it had no reaction, but Kan Chai felt dizzy after the time dose of the COVID-19 vaccine for emergency use in China.
“When I was driving on the road, I suddenly felt a little dizzy, like I was driving drunk,” the popular columnist said at a previous webinar this month. “So I discovered especially a position to prevent the car from resting a little and then I felt better.
This is a rare story among the thousands of people who won Chinese vaccines before final regulatory approval for general use. This is a resolution that poses moral and protection problems, as corporations and governments around the global rush to expand a vaccine to prevent the spread of the new coronavirus.
Chinese corporations caught the eye before administering the vaccine to their leading leaders and researchers even before human trials began to verify its protection and efficacy. In recent months, they have injected a much larger number of an emergency use designation approved in June, and that number appears to be about to increase.
A Chinese fitness official said Friday that China, which has largely eliminated the disease, will have to take steps to prevent it from returning, but an outdoor expert questioned the need for emergency use when the virus no longer spreads in the country. country where it was first detected.
It is not accurately known who and how many other people have injected so far, however, Chinese vaccine brands have presented clues. CNBG, Sinopharm’s state subsidiary, has administered the vaccine to another 350,000 people outside of its clinical trials, who have 40,000 registered employees, a senior CNBG executive recently said.
Another company, SinoVac, has injected 90% of its workers and members of the family circle, or about 3,000 people, the maximum under the emergency use provision, chief executive Yin Weidong said. He has also provided tens of thousands of cartridges for his CoronaVac to the Beijing city government.
Another candidate jointly developed through the army and Cansino, a biopharmaceutical company, has been for emergency use among army personnel.
“The first others to prioritize emergency use are researchers and vaccine manufacturers, because when the pandemic occurs, if those other people are infected, there is no way to produce the vaccine,” Yin said.
Now, major Chinese companies, along with Huawei telecommunications and Phoenix TV, have announced that they are working with Sinopharm to get the vaccine from their employees.
Several other people who say they paint in “frontline” organizations said on social media that their paint sites had vaccines for about 1,000 yuan ($150). They refused to comment, saying they would want permission from their organization.
In established but limited practice, the use of experimental drugs has traditionally been approved while still in the third and final phase of human trials. Chinese companies have 4 phase 3 vaccines: two from Sinopharm and one from SinoVac and Cansino.
The Chinese have referred to the World Health Organization’s principles of emergency use to create their own according to a strict process, a National Health Commission official, Zheng Zhongwei, said at a press conference on Friday.
He said there have been no serious effects in clinical trials.
“We’ve made it clear that the COVID-19 vaccine we use urgently is safe,” Zheng said. “Your protection would possibly be guaranteed, but its effectiveness has not yet been determined. “
According to the emergency rule, high-risk personnel, such as medical and customs personnel, and those who have to paint have priority access, he said, but refused to provide accurate figures.
“In China’s case, the pressure to save him imported infections and domestic resurgence remains enormous,” Zheng said.
But Diego Silva, a senior lecturer in bioethics at the University of Sydney, said giving vaccines to thousands of others in outdoor clinical trials had “no scientific merit” in China, where there are very few locally transmitted cases and arrivals lately. . are in central quarantine.
“If it’s in America, it’s not the only one in the world. But it’s not the first time Where the virus is still furious, it’s a little different, but in a country like China, it doesn’t make sense to me,” he said. “Because there are enough viruses in China at the local level to deduce something. “, introduces a number of other factors “by injecting other people outdoors into trials.
Zheng said that all other people injected as a component of emergency use are strictly monitored for any adverse effects on fitness.
Kan Chai, the columnist, wrote in an article published online in September that, despite his initial hesitations, registered after learning that a state-owned company was looking for volunteers.
It did not say whether this was an emergency use case, however, the timing of vaccination suggested that this is the case. He took the first dose at the end of July, when emergency vaccines began and trials were almost complete.
“I’m in a position to be a white mouse, and the main explanation is that I have confidence in our country’s vaccination technology,” he said.
His genuine call is Li Yong, however, his 1. 65 million fans on the social platform Twitter Weibo know him best through his pseudonym, which is “10 years cutting wood”. He declined an interview request.
He described taking the vaccine at a public webinar organized through 8 am HealthInsight, a popular fitness media outlet. It is known why he qualified to get it.
There is little data available to the public on the scope, duration and clinical price of the program. CNBG and parent company Sinopharm declined to comment. Zheng, an official of the National Health Commission, unaware of the Kan Chai case.
While emergency use may be the right way, Chinese corporations are not being transparent in problems such as informed consent, said Joy Zhang, a professor who studies the moral governance of emerging science at the University of Kent in the UK.
Zhang stated that it may locate any applicable data on the Sinopharm website in addition to general policies. Apart from reports published in foreign medical journals, there is much more made public.
He said more data would be made available to the public on other trials like the one conducted through the University of Oxford and AstraZeneca. The trial was stopped after a player developed severe neurological effects, and resumed only after clinical insights were presented. to an independent review panel.
China has a beyond vaccine problems, with scandals for more than two decades.
The most recent case dates back to 2018, when Changsheng Biotechnology Co. was investigated. for falsification of records and manufacture of useless vaccines for children.
In 2017, the Wuhan Co. Institute of Biological Products, a subsidiary of CNBG that initiated one of the vaccines in the Phase 3 trials, discovered that it had manufactured defective diphtheria vaccines that were ineffective.
Public anger over the case has led to a revision of the Vaccine Sanctions Act in 2019. The country has strengthened monitoring of the vaccine progression and distribution process and increased the implications for the manufacture of knowledge.
These considerations seem to be a thing of the past. Guizhen Wu, the leading biosecurity expert at the China Center for Disease Control, said a vaccine could be in a position for the general public in China as of November, and said she took an experimental vaccine in April.
An overseas worker at a Chinese state-owned company, who spoke under anonymity because it is not legal to speak to the media, said she would sign last week.
She said she wasn’t worried that a vaccine is a government priority, so the government will be watching the procedure closely.
———
Wu reported from Taipei, Taiwan. Associated Press manufacturer Olivia Zhang and videojournalist Dake Kang contributed to the report.
24/7 policy of the latest news and events